Cardiac Valve Prosthesis Cross-Linking Durability Thrombosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac valve replacement methods using mechanical or biological prostheses face challenges such as lifelong anticoagulation therapy for mechanical valves and limited durability and immune rejection for biological valves, with a need for a solution that balances durability and thrombosis prevention.
Innovation Solution
A method for manufacturing cardiac valve prostheses involving shaping and stabilizing human or animal body tissue using a cross-linking agent, allowing the tissue to maintain its shape and size, eliminating the need for additional support materials and reducing biodegradability, while using a secoiridoid-based cross-linking agent to enhance stability and biocompatibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If mechanical cardiac valves are used, then lifelong durability is achieved, but lifelong anticoagulation therapy is required to prevent thrombi
Solution Approach 1:
The patent applies parameter changes by modifying the surface properties of the prosthetic valve through plasma treatment and coating with biological materials (such as endothelial cells or extracellular matrix). This transforms the surface from a thrombogenic mechanical surface to a biocompatible surface that resists thrombus formation, allowing mechanical valves to be used without lifelong anticoagulation therapy while maintaining their durability
Solution Approach 2:
The patent uses composite materials by combining mechanical valve structures with biological coatings or hybrid materials that possess both mechanical strength and thromboresistance. This creates a composite prosthetic valve that integrates the durability of mechanical materials with the biocompatibility of biological materials, eliminating the need for anticoagulation therapy
2Object-affected harmful factors
If biological cardiac valves are used, then anticoagulation therapy is avoided, but durability is limited to 5-15 years due to immune rejection
Solution Approach 1:
The patent applies parameter changes by subjecting biological valve materials to cross-linking treatments (such as glutaraldehyde cross-linking or enzymatic cross-linking) that modify the biochemical properties of the tissue. This cross-linking process stabilizes the biological material, making it more resistant to enzymatic degradation and immune-mediated breakdown, thereby extending the durability of biological valves while maintaining their thromboresistant properties
Solution Approach 2:
The patent applies local quality by creating gradient structures in biological valves where different regions have different degrees of cross-linking or different material compositions. The inner surface that contacts blood may have different properties compared to the outer structural layers, optimizing both thromboresistance and durability in different functional zones of the valve
3Stability of the object's composition
If cross-linking agents are used to stabilize tissue, then structural integrity is improved, but biodegradability increases
Solution Approach 1:
The patent applies parameter changes by controlling the degree and type of cross-linking to achieve optimal balance between stability and durability. Using controlled cross-linking density and selecting cross-linking agents that provide stable bonds (such as carbodiimide cross-linking or genipin cross-linking) ensures that the tissue maintains structural integrity while resisting biodegradation over the long term
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a cardiac valve prosthesis with improved durability and reduced thrombosis risk, maintaining structural integrity and biocompatibility, with successful preclinical studies demonstrating long-term stability and integration with native tissue without significant immune response or thrombi formation.
Implementation Method 1
a fixation and stabilization of the body tissue by a cross-linking agent is carried out. In doing so, the shape given to the body tissue by the shaping process is preserved
Implementation Method 2
using a secoiridoid-based cross-linking agent to enhance stability and biocompatibility
Data Source
AI summary
A method for manufacturing a cardiac valve prosthesis is disclosed. This method comprises the following steps: a) shaping human or animal body tissue in a shaping process to give the body tissue a shape of a cardiac valve, and b) fixation and stabilization of the body tissue by a cross-linking agent, thereby preserving the shape given to the body tissue by the shaping process and thus obtaining a cardiac valve prosthesis. Furthermore, a method of implanting an autologous or allogenic cardiac valve prosthesis to an individual in need thereof is disclosed.